Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The company clearly has something important to say. It will be 8am in New York and some trial sites in USA could follow it if they tuned in early. A lot of effort usually goes into a webinar and the purpose is usually to heighten transparency between the company, its stakeholders and this includes investors. The probability is Synairgen has some kind of new data to share with us. It might concern long Covid-19 avoidance in some cases, or extending a study against the mu variant in Colombia or whatever. It may also be a case of running through the road map of what may follow if the trial is successful. I am not sure of any occasions when bad news is delivered by a webinar Q&A without a prior RNS. It is far more likely that engaging analysts would only take part if the data to be presented was having a meaningful impact as it would enable them to raise constructive questions about route to market, future financing, the value to patients and would this be the key to avoid UK lockdowns etcetera and issues about manufacturing to meet healthcare demands. It does not make a lot of sense to invite analysts to dissect a study that failed to meet its endpoints or did not have adequate efficacy. At any rate we have an interesting day in the diary to look forward to. Tony
I'm also hoping for some good news but it could just be a review of the interim results published earlier that day. Still, with our new appointees it ought to be a better presentation that the last one.
Very on point Tony, I hadn't considered the analyst angle and you are right when you say "It does not make a lot of sense to invite analysts to dissect a study that failed to meet its endpoints or did not have adequate efficacy".
On a separate note, I see the company have an open role for a PA/Training Coordinator. Reading the spec it seems the incumbent will be tasked with what I assume to be onboarding training material for new hires - a good sign further hiring may be on the horizon. On top of that diary management (Exec. level), travel and expenses. Also another sign that some key people will be travelling more than they were. You don't tend to track expenses at Exec level unless you will be doing a lot. Diary management is key on the Comms side of things - ensures adequate sign-off from the BOD on Communications/PR, etc. Small things but all pointing in the right direction.
I think this may tie in with Andy's point (ref SNG - who?) .. and also have reference to the new hirings (Comms etc) .. in that the webinar (having been addressed to analysts it seems) .. is to get the name and news further out into the world beyond just the small band of scientists, investors and believers so as to then have the awareness platform ready for the (imminent) BIG news of A2 & P3 results. Part of the big strategy.
Great post TT.
I am of a similar view of the scenario you have expressed. If this was to discuss results of 'poor' outcomes etc, it would have to be announced to the market immediately via RNS. I believe that they will be discussing a 'potential' roadmap and maybe, highlighting discussions that are ongoing with 'other' relevant parties about moving forward and the opportunities what has been achieved in the past months.
Looking forward to the update on 30th Sept :-)
Great post TT.
I am of a similar view of the scenario you have expressed. If this was to discuss results of 'poor' outcomes etc, it would have to be announced to the market immediately via RNS. I believe that they will be discussing a 'potential' roadmap and maybe, highlighting discussions that are ongoing with 'other' relevant parties about moving forward and the opportunities what has been achieved in the past months.
Looking forward to the update on 30th Sept :-)
poor grammar
'that' have etc
You wouldn't intentionally draw unnecessary attention to something negative.
I think if there was something noteworthy to report they can’t just sit on it for 2 weeks, they would have to announce it straight away. On this basis my prediction for the interims next week is no new data, but progress updates on all the trials and financials. More would be nice, but I don’t see how it’s possible.
Perhaps they they have been provided with a date when they will have results, and the webinar date has been set to reflect accordingly.